Avadel Pharmaceuticals plc each representing one Ordinary Share (AVDL): Price and Financial Metrics

Avadel Pharmaceuticals plc each representing one Ordinary Share (AVDL)

Today's Latest Price: $7.63 USD

0.02 (0.26%)

Updated Jul 9 4:00pm

Add AVDL to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 213 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

AVDL Stock Summary

  • With a price/sales ratio of 8.04, Avadel Pharmaceuticals Plc has a higher such ratio than 84.83% of stocks in our set.
  • AVDL's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of merely 1.48% of US stocks.
  • Revenue growth over the past 12 months for Avadel Pharmaceuticals Plc comes in at -36.33%, a number that bests merely 5.43% of the US stocks we're tracking.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Avadel Pharmaceuticals Plc are TMDX, NEU, TELL, ASX, and ALV.
  • AVDL's SEC filings can be seen here. And to visit Avadel Pharmaceuticals Plc's official web site, go to www.avadel.com.
AVDL Daily Price Range
AVDL 52-Week Price Range

AVDL Stock Price Chart Technical Analysis Charts

AVDL Price/Volume Stats

Current price $7.63 52-week high $13.49
Prev. close $7.61 52-week low $1.82
Day low $7.45 Volume 870,674
Day high $7.74 Avg. volume 825,239
50-day MA $8.49 Dividend yield N/A
200-day MA $7.19 Market Cap 285.74M

Avadel Pharmaceuticals plc each representing one Ordinary Share (AVDL) Company Bio

Avadel Pharmaceuticals plc develops and commercializes pharmaceutical products based on its proprietary drug delivery technology for primary care and sterile injectable markets in the United States, France, and Ireland. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. The company was founded in 1990 and is based in Dublin, Ireland.

AVDL Latest News Stream

Event/TimeNews Detail
Loading, please wait...

AVDL Latest Social Stream

Loading social stream, please wait...

View Full AVDL Social Stream

Latest AVDL News From Around the Web

Below are the latest news stories about Avadel Pharmaceuticals Plc that investors may wish to consider to help them evaluate AVDL as an investment opportunity.

Jazz Pharmaceuticals: Buy, Sell, Or Hold

Fate is just another word for people's choices coming to a head. Destiny, coincidence, whatever you name it. It inevitably lies in our hands." - Tiffanie DeBartolo It has been quite a while since we looked at this mid-cap biopharma below. The shares have seen better days, but there are...

Bret Jensen on Seeking Alpha | July 9, 2020

Bearish: Analysts Just Cut Their Avadel Pharmaceuticals plc (NASDAQ:AVDL) Revenue and EPS estimates

Market forces rained on the parade of Avadel Pharmaceuticals plc (NASDAQ:AVDL) shareholders today, when the analysts...

Yahoo | July 3, 2020

Avadel sells hospital sterile injectable drug portfolio for $42M

Avadel Pharmaceuticals ([[AVDL]] -1.4%) sold its portfolio of sterile injectable drugs used in the hospital setting, including three commercial products, Bloxiverz, Vazculep, and Akovaz, as well as Nouress to Exela Sterile Medicines LLC for a total of $42M.Avadel will receive $14.5M upfront and the remaining $27.5M will be paid over...

Seeking Alpha | July 1, 2020

Avadel Announces Sale of Hospital Sterile Injectable Drug Portfolio for $42.0 Million

Avadel Pharmaceuticals plc (AVDL), a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate for treating excessive daytime sleepiness and cataplexy in patients with narcolepsy, today announced the sale of its portfolio of sterile injectable drugs used in the hospital setting, including three commercial products, Bloxiverz®, Vazculep®, and Akovaz®, as well as Nouress™, which is approved by the U.S. Food and Drug Administration, to Exela Sterile Medicines LLC for a total of $42.0 million. “The sale of the sterile injectable drug portfolio is a significant milestone for the Company, as it further reflects our commitment to strategically focus on advancing FT218 through the regulatory review process and, if approved, bringing our once-nightly fo...

Yahoo | July 1, 2020

Hedge Funds Have Never Been More Bullish On Avadel Pharmaceuticals plc (AVDL)

The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. We at Insider Monkey have plowed through 821 13F filings that hedge funds and well-known value investors are required to file by the SEC. The 13F […]

Yahoo | June 28, 2020

Read More 'AVDL' Stories Here

AVDL Price Returns

1-mo -11.89%
3-mo N/A
6-mo 10.58%
1-year 219.25%
3-year -29.61%
5-year -64.94%
YTD 1.06%
2019 192.64%
2018 -68.54%
2017 -21.08%
2016 -14.91%
2015 -28.72%

Continue Researching AVDL

Want to see what other sources are saying about Avadel Pharmaceuticals Plc's financials and stock price? Try the links below:

Avadel Pharmaceuticals Plc (AVDL) Stock Price | Nasdaq
Avadel Pharmaceuticals Plc (AVDL) Stock Quote, History and News - Yahoo Finance
Avadel Pharmaceuticals Plc (AVDL) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Page generated in 0.9719 seconds.